Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Alkermes - The Untold Story

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1).

3 Biotech Stocks to Buy This Month and Beyond

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Value Stocks Investors Want

Strong recent economic data and still-elevated inflation are expected to keep the Fed on track for another interest rate hike next month. With the stock market likely to remain volatile amid rising interest rates and other macro uncertainties, fundamentally sound stocks Astellas (ALPMY), Alkermes (ALKS), and AstroNova (ALOT), trading at…

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

Change Healthcare Inc. (NASDAQ: CHNG) reported first-quarter fiscal 2023 adjusted earnings per share (ETF:EPS) of 38 cents, which missed the Zacks Consensus Estimate of 39 cents by 2.6%. The bottom line declined 7.3% on a year-over-year basis.

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Alkermes's Return On Capital Employed

Looking Into Alkermes's Return On Capital Employed

Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.

Recap: Alkermes Q1 Earnings

Recap: Alkermes Q1 Earnings

Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Alkermes's Earnings Outlook

Alkermes's Earnings Outlook

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will report an earnings per share (EPS) of $0.01.

Expert Ratings for Alkermes

Expert Ratings for Alkermes

Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter:

5 Outperforming Biotech Stocks with More Room to Run

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ). Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal Technology, enabling several products. Janssen partially terminated the agreements in the U.S., effective as of…

Get all your
news in one place.

100's of premium titles.
One news app.

Alkermes's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31% increase since Q3.

Why Are Alkermes Shares Trading Higher Today?

Alkermes plc's (NASDAQ: ALKS)

Recap: Alkermes Q4 Earnings

Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Preview For Alkermes

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will report an earnings per share (EPS) of $0.11.

Get all your
news in one place.

100's of premium titles.
One news app.

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

390,813 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play